Monte Rosa shares slide 30.7% after Q2 net loss

Monte Rosa Therapeutics shares fell 30.7% after the company disclosed a second-quarter net loss of $43.4 million, data showed. The results also indicated that the company’s losses expanded compared with the same quarter a year earlier, adding to investor pressure on the stock.

According to the figures reported by the company, the quarterly net loss widened from $12.3 million a year earlier. Basic and diluted loss per share rose to $0.43 from $0.15 over the same period.

Quarterly results show larger year-on-year loss

For the six months to June 30 The update also included first-half performance through June 30. For the six months to June 30, Monte Rosa moved from net income of $34.59 million to a net loss of $87.9 million, the company reported, marking a sharp reversal compared with the prior-year period. The company reported these results without issuing a new update on cash runway. In the absence of that detail, the release focused market attention on the scale of the quarterly loss and the larger first-half deficit. Investor focus turns to funding timeline and disclosures Following the release, investors sold heavily, reflecting concerns cited in the source material about near-term funding needs tied to clinical programs. The share-price move came immediately after the earnings figures, underlining how closely the market is tracking losses in smaller biotechnology companies.

Monte Rosa Therapeutics

The source material flagged September 30, 2026 as a key date for monitoring whether Monte Rosa provides a revised cash-runway figure or communicates a financing plan. It said such an update could be decisive for the stock and could be watched by peers as an indicator of funding conditions in small-cap biotech.

Uncertainty remains because the company did not provide a fresh cash-runway update alongside the quarterly loss. As a result, investors have limited new information in this release about how long existing resources may support ongoing programs or what financing steps, if any, may be pursued before the end of the third quarter.